Olvi-Vec plus chemotherapy for advanced small cell lung cancer
Part of Cancer clinical trials.
This trial tests a new drug called Olvi-Vec combined with standard chemotherapy (platinum plus etoposide) for people with advanced small cell lung cancer that has already been treated and is no longer responding. The goal is to see if this combination can help shrink tumors or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have small cell lung cancer (confirmed by a biopsy or cell test).
- Your cancer has gotten worse or come back after at least one type of standard treatment (like chemotherapy, immunotherapy, or anlotinib).
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are in good physical shape (ECOG score 0 or 1) and your main organs (bone marrow, liver, kidneys) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus standard chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination can be more effective than current treatments.
This trial tests a combination of benmelstobart (an immunotherapy drug), anlotinib (a targeted therapy that blocks blood vessel growth), chemotherapy, and chest radiation for people with extensive-stage small cell lung cancer (cancer that has spread beyond one lung). The goal is to see if this combination helps shrink tumors and control the disease better than standard care.
This trial tests different experimental drugs matched to the specific genetic makeup of your small cell lung cancer. The goal is to see if targeting your cancer's particular molecular type can shrink tumors or delay their growth better than standard care.
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Hear when a new SCLC, Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.